Seattle, Genetics Takeda Highlight Long-term Follow-up Data from ADCETRIS Pivotal Clinical Trials at ASH

Seattle Genetics (Nasdaq: SGEN ) and Takeda Pharmaceutical Company Limited (OTC: TKPYY ) today announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal